[
  {
    "question": {
      "question_id": "cs03_q05_negative",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "negative",
      "prompt": "Is there evidence of nephrotoxicity or renal dysfunction in enrolled subjects?",
      "ground_truth": {
        "canonical_answer": "No. Renal panels (creatinine, BUN, eGFR) remain within normal limits throughout the trial. The emerging safety signal is hepatic, not renal.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_004",
          "clinical_signal_03_ep_011"
        ],
        "key_facts": [
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q05_negative",
      "answer_text": "There is no evidence of nephrotoxicity or renal dysfunction in enrolled subjects based on the available information.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_5414b72b002a49a396362b19",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 520
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_5414b72b002a49a396362b19",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_4343d78eced0490ba8348729",
              "name": "memory_search",
              "arguments": {
                "query": "nephrotoxicity renal dysfunction enrolled subjects",
                "limit": 10
              }
            }
          ],
          "tokens_used": 603
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_4343d78eced0490ba8348729",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "There is no evidence of nephrotoxicity or renal dysfunction in enrolled subjects based on the available information.",
          "tokens_used": 639
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 1762,
      "wall_time_ms": 3058.137299027294,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q18_temporal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "temporal",
      "prompt": "When did the first hepatic enzyme elevations appear relative to drug exposure initiation?",
      "ground_truth": {
        "canonical_answer": "Hepatic enzyme elevations first appeared during the early signal phase, approximately weeks 9-10 of the trial, several weeks after subjects began receiving LNS-4821 with concomitant statin therapy.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q18_temporal",
      "answer_text": "I could not find any information regarding when the first hepatic enzyme elevations appeared relative to drug exposure initiation. The memory system did not return any relevant results for this query.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_2c638551014543d0836f875c",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 520
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_2c638551014543d0836f875c",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_4107ae0447034e8687055bd2",
              "name": "memory_search",
              "arguments": {
                "query": "first hepatic enzyme elevations timing after drug exposure initiation"
              }
            }
          ],
          "tokens_used": 597
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_4107ae0447034e8687055bd2",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I could not find any information regarding when the first hepatic enzyme elevations appeared relative to drug exposure initiation. The memory system did not return any relevant results for this query.",
          "tokens_used": 646
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 1763,
      "wall_time_ms": 4715.537486947142,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q19_distractor",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "distractor_resistance",
      "prompt": "Are novel urinary biomarkers (KIM-1, NGAL) showing any abnormalities in trial subjects?",
      "ground_truth": {
        "canonical_answer": "No. Renal biomarkers remain within normal limits. The emerging safety signal is hepatic (ALT/AST elevation), not renal.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_004",
          "clinical_signal_03_ep_011"
        ],
        "key_facts": [
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q19_distractor",
      "answer_text": "No information was found regarding abnormalities in novel urinary biomarkers (KIM-1, NGAL) in trial subjects.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_30d8d725d7044add90ff0fe1",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 525
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_30d8d725d7044add90ff0fe1",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_c64115db8f4f48aa9ff505ec",
              "name": "memory_search",
              "arguments": {
                "query": "novel urinary biomarkers KIM-1 NGAL abnormalities trial subjects",
                "limit": 10
              }
            }
          ],
          "tokens_used": 612
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_c64115db8f4f48aa9ff505ec",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "No information was found regarding abnormalities in novel urinary biomarkers (KIM-1, NGAL) in trial subjects.",
          "tokens_used": 650
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 1787,
      "wall_time_ms": 4056.1187349958345,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q24_evidence",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "evidence_sufficiency",
      "prompt": "Is there sufficient evidence at this point to convene a DSMB safety review?",
      "ground_truth": {
        "canonical_answer": "Borderline. The ALT trend in the statin subgroup is concerning but individual values are still below protocol action thresholds. A few more weeks of data showing continued escalation would strengthen the case for DSMB review.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q24_evidence",
      "answer_text": "I've attempted several searches related to DSMB and safety monitoring, but I haven't found any relevant information in the memory system. The searches for \"DSMB safety review,\" \"DSMB,\" and \"safety monitoring board\" all returned empty results.\n\nBased on the available information in the memory system, there is insufficient evidence to determine whether there is sufficient evidence to convene a DSMB safety review. The memory system does not contain any documents related to DSMBs, safety reviews, or similar monitoring processes that would help make this determination.",
      "turns": [
        {
          "role": "assistant",
          "content": "I need to check if there is sufficient evidence to convene a DSMB safety review. First, let me understand the capabilities of the memory system to determine the best approach for retrieving relevant information.",
          "tool_calls": [
            {
              "id": "call_74e9224f6c72457d811ccc0d",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 559
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_74e9224f6c72457d811ccc0d",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The memory system supports semantic search, which will help me find relevant information about DSMB safety reviews and evidence criteria. Let me search for information related to DSMB (Data and Safety Monitoring Board) safety reviews and the evidence required to convene one.",
          "tool_calls": [
            {
              "id": "call_49cceb5ed8924c449b7b80d2",
              "name": "memory_search",
              "arguments": {
                "query": "DSMB safety review evidence criteria",
                "limit": 10
              }
            }
          ],
          "tokens_used": 688
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_49cceb5ed8924c449b7b80d2",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I couldn't find any information regarding DSMB safety review evidence criteria in the memory system. Let me try a broader search to see if there's any related information about DSMB or safety reviews.",
          "tool_calls": [
            {
              "id": "call_a625374afa334b6287c4cd6f",
              "name": "memory_search",
              "arguments": {
                "query": "DSMB safety review",
                "limit": 10
              }
            }
          ],
          "tokens_used": 770
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_a625374afa334b6287c4cd6f",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I still haven't found any information about DSMB safety reviews. Let me try searching for more general terms related to safety monitoring or clinical trial oversight, which might provide relevant context.",
          "tool_calls": [
            {
              "id": "call_4d3dbf6b5e864260a857dc1e",
              "name": "memory_search",
              "arguments": {
                "query": "safety monitoring board",
                "limit": 10
              }
            }
          ],
          "tokens_used": 849
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_4d3dbf6b5e864260a857dc1e",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I've attempted several searches related to DSMB and safety monitoring, but I haven't found any relevant information in the memory system. The searches for \"DSMB safety review,\" \"DSMB,\" and \"safety monitoring board\" all returned empty results.\n\nBased on the available information in the memory system, there is insufficient evidence to determine whether there is sufficient evidence to convene a DSMB safety review. The memory system does not contain any documents related to DSMBs, safety reviews, or similar monitoring processes that would help make this determination.",
          "tokens_used": 972
        }
      ],
      "tool_calls_made": 4,
      "total_tokens": 3838,
      "wall_time_ms": 14269.191890954971,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  }
]